U.S. stocks were higher, with the Nasdaq Composite gaining more than 150 points on Thursday.

Shares of Aehr Test Systems (NASDAQ:AEHR) rose sharply during Thursday’s session after the company announced it received an additional follow-on production order from its lead silicon photonics customer for a fully automated FOX-XP wafer-level burn-in system.

Aehr Test Systems shares climbed 13.6% to $77.18 on Thursday.

Here are some other big stocks recording gains in today’s session.

• Forte Biosciences Inc (NASDAQ:FBRX) shares jumped 43.6% to $29.56 after reporting results from FB102 double-blind placebo-controlled Phase 1b study in Vitiligo.
• BridgeBio Pharma Inc (NASDAQ:BBIO) gained 17.3% to $91.86.
• First Tracks Biotherapeutics Inc (NASDAQ:TRAX) jumped 13.6% to $23.60.
• Nlight Inc (NASDAQ:LASR) gained 13.3% to $66.50.
• Onto Innovation Inc (NYSE:ONTO) rose 13% to $329.50.
• Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) jumped 12.5% to $364.00.
• Ichor Holdings, Ltd (NASDAQ:ICHR) gained 12.1% to $99.55.
• Lumentum Holdings Inc (NASDAQ:LITE) gained 11% to $785.18.
• Arm Holdings PLC – ADR (NASDAQ:ARM) climbed 10.7% to $332.42.
• Lam Research Corp (NASDAQ:LRCX) gained 10.7% to $368.68. Mizuho analyst Vijay Rakesh maintained Lam Research with an Outperform rating and raised the price target from $380 to $400.
• KLA Corp (NASDAQ:KLAC) shares rose 10.6% to $244.78.
• FormFactor Inc (NASDAQ:FORM) gained 10.2% to $122.94. FormFactor will announce second quarter 2026 financial results on July 29.
• Amkor Technology Inc (NASDAQ:AMKR) gained 9.8% to $73.52.
• Applied Materials Inc (NASDAQ:AMAT) rose 9.8% to $626.58. Mizuho analyst Vijay Rakesh maintained Applied Materials with an Outperform rating and raised the price target from $540 to $650.
• Ciena Corp (NYSE:CIEN) rose 9.6% to $483.28.
• Kulicke And Soffa Industries Inc (NASDAQ:KLIC) gained 8.8% to $113.50.
• ON Semiconductor Corp (NASDAQ:ON) gained 8.1% to $101.40.
• Advanced Micro Devices Inc (NASDAQ:AMD) rose 7.4% to $556.00.

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.